Latest News
Lysogene concludes patient recruitment in SAMOS trial for MPS IIIA
French biopharmaceutical firm Lysogene has completed patient enrolment for its Sanfilippo A multi-national observational study (SAMOS) to treat mucopolysaccharidosis type IIIA (MPS IIIA),...
Suramin demonstrates positive outcome in University of California’s autism study
Prescient pauses enrolment for PTX-200 trials to investigate a SAE
Australian-based oncology firm Prescient Therapeutics has temporarily paused enrolment in the clinical trials of its product candidate PTX-200 to further investigate a serious adverse event...
Tracon Pharma commences dosing in Phase I/II trial of TRC253 to treat mCRPC
US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has started dosing patients in the Phase I/II clinical trial of TRC253 for the treatment of metastatic...
X4 Pharmaceuticals begins Phase II trial of X4P-001 to treat ccRCC
Northwestern Medicine initiates Phase I trial of stem cells + cold virus for glioma
Akebia doses first patient in Phase II trial of vadadustat to treat DD-CKD
US-based biopharmaceutical firm Akebia Therapeutics has started dosing patients in its Phase II FO2RWARD clinical trial of vadadustat for the treatment of patients with dialysis-dependent...
Neurocrine’s Ingrezza fails to meet primary endpoint in Phase II trial for Tourette syndrome
US-based biotechnology firm Neurocrine Biosciences’ Ingrezza (valbenazine) has failed to meet the primary endpoint in its Phase II T-Force GREEN clinical trial to treat Tourette...
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial of HP Acthar gel to manage exacerbations in relapsing and remitting...
UNS reports positive results from Phase I trial of UB-311 to treat Alzheimer’s disease
United Neuroscience (UNS) has reported positive results from the Phase I clinical trial of UB-311 for the treatment of patients suffering from Alzheimer’s disease...
AstraZeneca’s Phase III trial shows benralizumab minimises OCS use in asthma patients
Amgen’s Repatha shows positive outcome in Phase III trial for cardiovascular disease
Celgene’s Phase III trial of ozanimod for RMS meets primary endpoint
US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of ozanimod for the treatment of relapsing multiple sclerosis (RMS)...
ViaCyte to study PEC-Direct in international clinical trial for type 1 diabetes
US-based regenerative medicine firm ViaCyte has obtained approval for its investigational new drug (IND) application from both the US Food and Drug Administration and Health Canada to initiate...
Shire’s lanadelumab and SHP647 meet endpoints in respective trials
Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II...
Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis
Albireo to initiate A4250’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive...
Medical research funders and NGOs agree on new WHO clinical trial policies
Aurinia begins voclosporin dosing in Phase III trial for LN
Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis...
Interface Clinical Research develops new GP model to minimise clinical trial drop outs
Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical...
Syndax’s entinostat advances into second stage of Phase II trial for NSCLC
US-based biopharmaceutical firm Syndax Pharmaceuticals’ entinostat has advanced into the second stage of Phase II of the ENCORE 601 clinical trial for the treatment of patients with non-small...
